Top Markets
#1 Purr Purr +62.18%
#2 Smilek to the Bank Smilek to the Bank +50.56%
#3 Pons Pons +27.54%
#4 Kinetiq Kinetiq +24.51%
#5 ApeX ApeX +23.35%
#6 Fake World Assets Fake World Assets +19.18%
#7 Zora Zora +18.85%
#8 Non-Playable Coin Non-Playable Coin +18.72%
#9 Not in Employment, Education, or Training Not in Employment, Education, or Training +18.50%
#10 OriginTrail OriginTrail +18.33%
Coin of the day
Purr Purr
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Talaris Therapeutics, Inc. Talaris Therapeutics, Inc.

Talaris Therapeutics, Inc.

TALS
Clasificación en acciones #21258
Talaris Therapeutics, Inc. is a cell therapy company operating in the United... Talaris Therapeutics, Inc. is a cell therapy company operating in the United States, currently in its late clinical development stages. Its mission involves pioneering an allogeneic hematopoietic stem cell transplantation strategy designed to revolutionize treatment paradigms for solid organ transplantation, severe autoimmune conditions, and significant non-malignant blood, immune, and metabolic disorders. The company's flagship product, FCR001, is an innovative allogeneic cell therapy presently in Phase II clinical trials for patients undergoing living donor kidney transplantation. Beyond this, Talaris Therapeutics is actively advancing FCR002 for use in deceased donor kidney transplants, investigating FCR001 for individuals with a severe form of scleroderma, and exploring its applicability for a range of other serious non-malignant blood, immune, or metabolic conditions. Founded in 1988, the company maintains its headquarters in Louisville, Kentucky.
Precio por acción
$2.72
Última sincronización: 2023-10-19
Capitalización bursátil
$111.47M
Cambio (1 día)
-0.73%
Cambio (1 año)
0.00%
País
US
Comercio Talaris Therapeutics, Inc. (TALS)

Categoría

Healthcare
Ingresos de Talaris Therapeutics, Inc. (TALS)
Ingresos en Aug 2026 TTM: 0
Según los últimos informes financieros de Talaris Therapeutics, Inc., los ingresos actuales de la empresa (TTM) son 0. En 2026, la empresa obtuvo unos ingresos de 0 igual a los ingresos del año 2026, que fueron de 0. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Talaris Therapeutics, Inc. desde 2026 hasta 2026
Ingresos al final de cada año
Año Ingresos Cambiar
Not enough data for the provided dates.
Ingresos de empresas similares o competidoras
Empresa Ingresos Diferencia de ingresos País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH